Horikawa, Chika
Tsuda, Kinsuke
Oshida, Yoshiharu
Satoh, Jo
Hayashino, Yasuaki
Tajima, Naoko
Nishimura, Rimei
Sone, Hirohito
Koya, Daisuke
Shikata, Kenichi
Kitano, Shigehiko
Sato, Yukihiro
Yamashita, Hidetoshi
Kato, Satoshi
Nakamura, Jiro
Baba, Masayuki
Shimano, Hitoshi
Yamasaki, Yoshimitsu
Yoshioka, Naruhito
Sasaki, Satoshi
Sato, Jo
Tsuda, Kinsuke
Oshida, Yoshiharu
Sone, Hirohito
Izumi, Kazuo
Origasa, Hideki
Nishimura, Rimei
Hayashino, Yasuaki
Inagaki, Kouji
Nishimura, Fusanori
Noguchi, Hidetoshi
Yoshioka, Naruhito
Sato, Jo
Nishimura, Rimei
Nakamura, Jiro
Inagaki, Nobuya
Tanizawa, Yukio
Araki, Eiichi
Araki, Eiichi
Izumi, Kazuo
Inagaki, Nobuya
Ueki, Kohjiro
Sone, Hirohito
Tajima, Naoko
Nishimura, Yukio Tanizawa Rimei
Noda, Mitsuhiko
Hayashino, Yasuaki
Iwamoto, Yasuhiko
Kasuga, Masato
Nanjo, Kishio
Haneda, Masakazu
Hotta, Nigishi
Kasuga, Masato
Iso, Yasuhiro
Kiyohara, Hiroshi
Haneda, Masakazu
Yamauchi, Toshimasa
Yamazaki, Tsutomu
Araki, Eiichi
Nakamura, Jiro
Iso, Yasuhiro
Kiyohara, Hiroshi
Yamauchi, Toshimasa
Yamazak., Tsutomu
,
Funding for this research was provided by:
Japan Diabetes Society
Article History
Received: 8 December 2021
Accepted: 23 February 2022
First Online: 24 March 2022
Declarations
:
: Jo Satoh received honoraria from Boehringer Ingelheim, Eli Lilly and Company, MSD, Ono Pharmaceutical Co., Ltd., Sanofi, and Sumitomo Dainippon Pharma Co., Ltd. Yasuaki Hayashino received a research grant from Ono Pharmaceutical Co., Ltd. Rimei Nishimura received honoraria from Sanofi, Medtronic Japan Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., MSD, and Astellas Pharma lnc., and received subsidies or donations from Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., and Nippon Boehringer Ingelheim Co., Ltd. Hirohito Sone received a research grant from Novo Nordisk Pharma Ltd., and reports endowed departments by commercial entities from Novo Nordisk Pharma Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd. Astellas Pharma Inc., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Chika Horikawa, Kinsuke Tsuda, Yoshiharu Oshida, and Naoko Tajima declare that they have no conflict of interest.
: The protocol for the study, which is in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical/Epidemiological Studies of the Japanese Ministry of Health Labor and Welfare, received ethical approval from the institutional review boards of the Japan Diabetes Society Research Ethics Committee and all of the participating institutes, and was registered with the UMIN Clinical Trial Registry (Registry ID UMIN000016519).
: Written informed consent was obtained from all patients enrolled to protect their rights and welfare, and to protect them against any potential harm and risk associated with the conduct of the study.